A Patient-Clinician Discussion of Current Challenges in Schizophrenia Part 1: Addressing Daily Functioning and Cognitive Impairments Associated with Schizophrenia [Podcast]

Overview

Journal Neuropsychiatr Dis Treat

Publisher Dove Medical Press

Specialty Psychiatry

Date 2023 Jun 9

PMID 37292181

Authors

Carlos A Larrauri

Philip D Harvey

John M Kane

Affiliations

Soon will be listed here.

Abstract

Dr John M. Kane discusses cognitive impairments in schizophrenia with fellow expert Dr Philip D. Harvey and patient advocate and mental health clinician, Mr Carlos A. Larrauri, who was diagnosed with schizophrenia. The podcast aims to raise awareness of the unmet need to address cognitive impairments associated with schizophrenia (CIAS) as well as the challenges/opportunities faced by patients and clinicians regarding assessments and treatments. The authors emphasize the importance of a treatment focus on daily functioning, in parallel with cognitive symptoms, to mitigate impairments and improve overall outcomes. Mr Larrauri presents the patient perspective and shares his experiences of how psychosocial support and cognitive training can benefit recovery and help patients achieve their goals.

References

Kharawala S, Hastedt C, Podhorna J, Shukla H, Kappelhoff B, Harvey P . The relationship between cognition and functioning in schizophrenia: A semi-systematic review. Schizophr Res Cogn. 2021; 27:100217. PMC: 8488595. DOI: 10.1016/j.scog.2021.100217. View

Rosell D, Zaluda L, McClure M, Perez-Rodriguez M, Strike K, Barch D . Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder. Neuropsychopharmacology. 2014; 40(2):446-53. PMC: 4443959. DOI: 10.1038/npp.2014.192. View

Biagianti B, Fisher M, Brandrett B, Schlosser D, Loewy R, Nahum M . Development and testing of a web-based battery to remotely assess cognitive health in individuals with schizophrenia. Schizophr Res. 2019; 208:250-257. PMC: 6544475. DOI: 10.1016/j.schres.2019.01.047. View

Spark D, Fornito A, Langmead C, Stewart G . Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics. Transl Psychiatry. 2022; 12(1):147. PMC: 8991275. DOI: 10.1038/s41398-022-01904-2. View

Jones M, Strassnig M, Harvey P . Emerging 5-HT receptor antagonists for the treatment of Schizophrenia. Expert Opin Emerg Drugs. 2020; 25(2):189-200. DOI: 10.1080/14728214.2020.1773792. View

Keefe R, Haig G, Marder S, Harvey P, Dunayevich E, Medalia A . Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia. Schizophr Bull. 2015; 42(1):19-33. PMC: 4681562. DOI: 10.1093/schbul/sbv111. View

Silberstein J, Pinkham A, Penn D, Harvey P . Self-assessment of social cognitive ability in schizophrenia: Association with social cognitive test performance, informant assessments of social cognitive ability, and everyday outcomes. Schizophr Res. 2018; 199:75-82. PMC: 6151277. DOI: 10.1016/j.schres.2018.04.015. View

Kreyenbuhl J, Record E, Himelhoch S, Charlotte M, Palmer-Bacon J, Dixon L . Development and Feasibility Testing of a Smartphone Intervention to Improve Adherence to Antipsychotic Medications. Clin Schizophr Relat Psychoses. 2016; 12(4):152-167. PMC: 5910284. DOI: 10.3371/CSRP.KRRE.070816. View

Cella M, Okruszek L, Lawrence M, Zarlenga V, He Z, Wykes T . Using wearable technology to detect the autonomic signature of illness severity in schizophrenia. Schizophr Res. 2017; 195:537-542. DOI: 10.1016/j.schres.2017.09.028. View

10.

Shmukler A, Gurovich I, Agius M, Zaytseva Y . Long-term trajectories of cognitive deficits in schizophrenia: A critical overview. Eur Psychiatry. 2015; 30(8):1002-10. DOI: 10.1016/j.eurpsy.2015.08.005. View

11.

McClure M, Barch D, Romero M, Minzenberg M, Triebwasser J, Harvey P . The effects of guanfacine on context processing abnormalities in schizotypal personality disorder. Biol Psychiatry. 2006; 61(10):1157-60. DOI: 10.1016/j.biopsych.2006.06.034. View

12.

Murante T, Cohen C . Cognitive Functioning in Older Adults With Schizophrenia. Focus (Am Psychiatr Publ). 2020; 15(1):26-34. PMC: 6519630. DOI: 10.1176/appi.focus.20160032. View

13.

Harvey P, Miller M, Moore R, Depp C, Parrish E, Pinkham A . Capturing Clinical Symptoms with Ecological Momentary Assessment: Convergence of Momentary Reports of Psychotic and Mood Symptoms with Diagnoses and Standard Clinical Assessments. Innov Clin Neurosci. 2021; 18(1-3):24-30. PMC: 8195558. View

14.

Keefe R . Why are there no approved treatments for cognitive impairment in schizophrenia?. World Psychiatry. 2019; 18(2):167-168. PMC: 6502426. DOI: 10.1002/wps.20648. View

15.

Lavigne K, Sauve G, Raucher-Chene D, Guimond S, Lecomte T, Bowie C . Remote cognitive assessment in severe mental illness: a scoping review. Schizophrenia (Heidelb). 2022; 8(1):14. PMC: 8897553. DOI: 10.1038/s41537-022-00219-x. View

16.

. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022; 9(2):137-150. PMC: 8776563. DOI: 10.1016/S2215-0366(21)00395-3. View

17.

Paolillo E, Lee S, VandeBunte A, Djukic N, Fonseca C, Kramer J . Wearable Use in an Observational Study Among Older Adults: Adherence, Feasibility, and Effects of Clinicodemographic Factors. Front Digit Health. 2022; 4:884208. PMC: 9231611. DOI: 10.3389/fdgth.2022.884208. View

18.

Harvey P, Horan W, Atkins A, Stevens H, Welch M, Yuan J . Factor structure of cognitive performance and functional capacity in schizophrenia: Evidence for differences across functional capacity measures. Schizophr Res. 2020; 223:297-304. PMC: 7704623. DOI: 10.1016/j.schres.2020.08.010. View

19.

Reinertsen E, Clifford G . A review of physiological and behavioral monitoring with digital sensors for neuropsychiatric illnesses. Physiol Meas. 2018; 39(5):05TR01. PMC: 5995114. DOI: 10.1088/1361-6579/aabf64. View

20.

Wu Q, Wang X, Wang Y, Long Y, Zhao J, Wu R . Developments in Biological Mechanisms and Treatments for Negative Symptoms and Cognitive Dysfunction of Schizophrenia. Neurosci Bull. 2021; 37(11):1609-1624. PMC: 8566616. DOI: 10.1007/s12264-021-00740-6. View